This Trend Is the Biggest Risk to Biotech Investors Right Now
It's been a rough 12 months for biotechnology stocks. Over a period when the broad market has risen by 12.9%, shares of the industry-tracking SPDR S&P Biotech ETF (NYSEMKT: XBI) are down by more than 43%.
But what could have caused such a steep drop when the ETF holds stakes in such a wide array of biotechs? After all, it's hard to believe that so many of those companies could have experienced setbacks during the same period.
Image source: Getty Images.
Source Fool.com
